Additionally, potential futuretherapeutic agents for prevention or treatment of liver diseases bytargeting hepatic mARC1, either by siRNA approaches, proteolysis targetingchimeras (PROTAC), or traditional small-molecule inhibitors, can beexpected to increase blood levels of NHU in patients who are treatedwith this drug. This evidence concerns the gene MTARC1 and liver disorder.